三民網路書店 / 搜尋結果

Cell therapy is a rapidly developing area, drawing on cell biology, molecular biology, virology, immunology, cell quantitation techniques and biomedical engineering. It has potential in many clinical settings, in the treatment of cancer and other diseases. This volume in the series Cancer: Clinical Science in Practice examines the current state and future prospects of cell therapy, which seems likely to have an even more profound impact on health care than did the production of proteins by recombinant DNA technology. The coverage is broad, including the scientific principles of haematopoietic cell therapy, the technology of cell collection and preparation, current and likely future clinical applications of cell therapy, and the principles and practice of cellular immunotherapy. Up-to-date and authoritative, volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management

The development of drug-resistant cancers is considered to be the most significant obstacle to the cure of cancer today. Nearly half of all patients with cancer suffer from tumours that are intrinsically resistant to chemotherapy, and most of the remaining half develop drug resistance during the course of their treatment. This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority. Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support. The authors are among the leading clinicians and investigators in the field. These authoritative volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

One third of human cancers have a hormonal basis. Breast cancer, the most common cancer of women, is increasing in incidence in many countries, as, in epidemic proportions, is prostate cancer, the second most common cancer of men. Concurrently, the development of molecular biology has led to a refinement of the definition of hormones to include the complex interaction between tumour cells and both locally and distantly secreted factors. This 1996 volume from the series Cancer: Clinical Science in Practice considers the many aspects of hormonally dependent cancer, including the molecular basis for the autocrine and paracrine regulation of cancer, molecular strategies for cancer detection, preventive strategies in limiting the epidemic of hormonally related cancers, and treatment approaches. The concise volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the application of biomedical science to the understanding and management of

The clinical applications of human gene therapy have been particularly fruitful in oncology, and in the last few decades there has been explosive growth in understanding of the genetic lesions leading to neoplasia. This volume in the series Cancer: Clinical Science in Practice reviews progress in the basic and clinical science of gene therapy in oncology, and looks forward to future developments. It considers what has worked and what has not in the fast-evolving field of gene therapy, drawing on laboratory studies and clinical trials, including the work of the contributors themselves. Topical and authoritative, volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

The development of drug-resistant cancers is considered to be the most significant obstacle to the cure of cancer today. Nearly half of all patients with cancer suffer from tumours that are intrinsically resistant to chemotherapy, and most of the remaining half develop drug resistance during the course of their treatment. This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority. Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support. The authors are among the leading clinicians and investigators in the field. These authoritative volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.